2020
Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes
Frenster J, Kader M, Kamen S, Sun J, Chiriboga L, Serrano J, Bready D, Golub D, Ravn-Boess N, Stephan G, S A, Kurz S, Jain R, Park C, Fenyo D, Liebscher I, Schöneberg T, Wiggin G, Newman R, Barnes M, Dickson J, MacNeil D, Huang X, Shohdy N, Snuderl M, Zagzag D, Placantonakis D. Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes. Neuro-Oncology Advances 2020, 2: vdaa053. PMID: 32642706, PMCID: PMC7262742, DOI: 10.1093/noajnl/vdaa053.Peer-Reviewed Original ResearchAdult gliomasIsocitrate dehydrogenase wild-type tumorsWild-type tumorsLimited treatment optionsBrain tissueNon-neoplastic brain tissuesTumor bulkAdvanced malignanciesGlioma familiesTumor specimensTumor marginsMutant gliomasAdult glioblastomaWHO gradeNovel therapiesTreatment optionsTumor growthGlioma subtypesBrain malignanciesTumorGliomaWild-typeIsocitrate dehydrogenaseMalignancyGlioblastoma
2019
Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma
Spino M, Kurz S, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara C, Frenster J, Tateishi K, Wakimoto H, Jain R, Riina H, Nicolaides T, Sulman E, Cahill D, Golfinos J, Isse K, Saunders L, Zagzag D, Placantonakis D, Snuderl M, S. A. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma. Clinical Cancer Research 2019, 25: 1261-1271. PMID: 30397180, PMCID: PMC7365589, DOI: 10.1158/1078-0432.ccr-18-2312.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedBenzodiazepinonesBrainDNA MethylationFemaleGene Expression Regulation, NeoplasticGenotypeGliomaHumansImmunoconjugatesIntracellular Signaling Peptides and ProteinsIsocitrate DehydrogenaseLigandsMaleMembrane ProteinsMolecular Targeted TherapyMutationNeoplasm Recurrence, LocalReceptors, NotchRNAConceptsGlioma molecular subtypesAntibody-drug conjugatesMolecular subtypesCell surface tumor-associated antigensTumor-associated antigensWild-type glioblastomaAntigen-dependent mannerLow-grade gliomasRova-TRecurrent tumorsDLL3 expressionRovalpituzumab tesirineNontumor brain tissuesNontumor brainMutant gliomasTherapeutic strategiesCell viability assayGliomaRNA levelsDLL3TumorspheresTherapeutic targetIHCTCGA dataWild-type